Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Alliance with Nichi-Iko “Not Due to Pessimism about Generic Drug Business,” Will Expand Lineup: Eisai CEO
Eisai CEO Haruo Naito said on March 29 that his company has decided to transfer the entire stake in its wholly owned subsidiary Elmed Eisai to Nichi-Iko Pharmaceutical because it expects the role of generic drugs to continue growing, not…
To read the full story
Related Article
- Nichi-Iko Takes Full Control of Eisai Generic Arm, Now Renamed “Elmed”
April 2, 2019
- Nichi-Iko to Raise 21.2 Billion Yen for Elmed Eisai Buyout
April 5, 2018
- Eisai’s Nichi-Iko Deal Marks Watershed in Generic Biz of Research-Driven Makers
April 3, 2018
- Eisai to Quit Generic Supply Biz, Transfer Subsidiary to Nichi-Iko
March 29, 2018
BUSINESS
- Otsuka to Acquire Transcend for US$700 Million, Snags PTSD Candidate
March 30, 2026
- Eisai, MSD File Lenvima-Welireg Combo in Japan for RCC
March 30, 2026
- Chugai CEO Takes Home 441 Million Yen in 2025: Securities Report
March 30, 2026
- Takeda to Resume MR Vaccine Shipments in June after Potency Issue
March 30, 2026
- Kyowa Kirin’s Mullick Earns 263 Million Yen in 2025; Workforce Down Sharply
March 30, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…